BACKGROUND: Chronic hepatitis C virus (HCV) infection is characterized by reduced numbers of functional HCV-specific T cells. In addition, chronically HCV-infected individuals have reduced response to vaccine. Alterations in naive CD4 T cell phenotype or function may contribute to these immune impairments. METHODS: Using flow cytometric analysis and enzyme-linked immunospot assay, we examined peripheral naive CD4 T cell phenotype and function in chronically HCV-infected patients and control subjects. RESULTS: We observed significantly lower absolute cell numbers of naive CD4 T cells in HCV-infected patients, localized to the CD127(+)CD25(low/-) and CD31(+) (RTE) subsets. Moreover, we found greater percentages of naive cells expressing CD25 and KI67 in HCV-infected patients, consistent with immune activation, further supported by higher plasma sCD27 levels. Functional analysis revealed an intact interferon-γ response to allogeneic B cell stimulus. However, after direct TCR stimulation, naive CD4 T cells from HCV-infected patients had altered up-regulation of KI67 and CD25 and less CD27 expression. The latter was associated with elevated baseline activation state. In addition, naive CD4 T cells from HCV-infected patients were more susceptible to cell death. CONCLUSIONS: These numerical and functional defects may contribute to inadequate formation of virus and neoantigen-specific T cell responses during chronic HCV infection.
BACKGROUND:Chronic hepatitis C virus (HCV) infection is characterized by reduced numbers of functional HCV-specific T cells. In addition, chronically HCV-infected individuals have reduced response to vaccine. Alterations in naive CD4 T cell phenotype or function may contribute to these immune impairments. METHODS: Using flow cytometric analysis and enzyme-linked immunospot assay, we examined peripheral naive CD4 T cell phenotype and function in chronically HCV-infectedpatients and control subjects. RESULTS: We observed significantly lower absolute cell numbers of naive CD4 T cells in HCV-infectedpatients, localized to the CD127(+)CD25(low/-) and CD31(+) (RTE) subsets. Moreover, we found greater percentages of naive cells expressing CD25 and KI67 in HCV-infectedpatients, consistent with immune activation, further supported by higher plasma sCD27 levels. Functional analysis revealed an intact interferon-γ response to allogeneic B cell stimulus. However, after direct TCR stimulation, naive CD4 T cells from HCV-infectedpatients had altered up-regulation of KI67 and CD25 and less CD27 expression. The latter was associated with elevated baseline activation state. In addition, naive CD4 T cells from HCV-infectedpatients were more susceptible to cell death. CONCLUSIONS: These numerical and functional defects may contribute to inadequate formation of virus and neoantigen-specific T cell responses during chronic HCV infection.
Authors: R Q Hintzen; R de Jong; C E Hack; M Chamuleau; E F de Vries; I J ten Berge; J Borst; R A van Lier Journal: J Immunol Date: 1991-07-01 Impact factor: 5.422
Authors: M Wiedmann; U G Liebert; U Oesen; H Porst; M Wiese; S Schroeder; U Halm; J Mössner; F Berr Journal: Hepatology Date: 2000-01 Impact factor: 17.425
Authors: R Arens; K Tesselaar; P A Baars; G M van Schijndel; J Hendriks; S T Pals; P Krimpenfort; J Borst; M H van Oers; R A van Lier Journal: Immunity Date: 2001-11 Impact factor: 31.745
Authors: Kevin L Steiner; Indu Malhotra; Peter L Mungai; Eric M Muchiri; Arlene E Dent; Christopher L King Journal: Virology Date: 2012-01-26 Impact factor: 3.616
Authors: Robert Sanchez Rodriguez; Mariela L Pauli; Isaac M Neuhaus; Siegrid S Yu; Sarah T Arron; Hobart W Harris; Sara Hsin-Yi Yang; Bryan A Anthony; Francis M Sverdrup; Elisabeth Krow-Lucal; Tippi C MacKenzie; David S Johnson; Everett H Meyer; Andrea Löhr; Andro Hsu; John Koo; Wilson Liao; Rishu Gupta; Maya G Debbaneh; Daniel Butler; Monica Huynh; Ethan C Levin; Argentina Leon; William Y Hoffman; Mary H McGrath; Michael D Alvarado; Connor H Ludwig; Hong-An Truong; Megan M Maurano; Iris K Gratz; Abul K Abbas; Michael D Rosenblum Journal: J Clin Invest Date: 2014-02-10 Impact factor: 14.808
Authors: Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Angela L Rasmussen; I-Ming Wang; Margaret C Shuhart; Sean C Proll; Yudong He; Razvan Cristescu; Chris Roberts; Victoria S Carter; Christopher M Williams; Deborah L Diamond; Janine T Bryan; Roger Ulrich; Marcus J Korth; Lisa V Thomassen; Michael G Katze Journal: Virology Date: 2012-05-16 Impact factor: 3.616
Authors: Chelsey J Judge; Johan K Sandberg; Nicholas T Funderburg; Kenneth E Sherman; Adeel A Butt; Minhee Kang; Alan L Landay; Michael M Lederman; Donald D Anthony Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Jessica A Hutter Saunders; Katherine A Estes; Lisa M Kosloski; Heather E Allen; Kathryn M Dempsey; Diego R Torres-Russotto; Jane L Meza; Pamela M Santamaria; John M Bertoni; Daniel L Murman; Hesham H Ali; David G Standaert; R Lee Mosley; Howard E Gendelman Journal: J Neuroimmune Pharmacol Date: 2012-10-11 Impact factor: 4.147